This statement has been published in accordance with the Modern Slavery Act 2015. It provides an update on the progress that Roche Products Limited, Roche Diagnostics Limited and Roche Diabetes Care Limited have made during the financial year ending 31 December 2022, and will continue to make, to prevent modern slavery in their businesses and supply chains. Unless otherwise specified, all references to Roche herein are references to the Roche UK entities.

F Hoffmann-La Roche Limited was founded in Switzerland in 1896 and has had a presence in the United Kingdom since 1908. Headquartered in Basel, Switzerland Roche now operates in over 100 countries with over 91,000 employees around the world.

Roche plays a significant role in not only driving medical advancement but also in offering a broad and innovative portfolio of products to patients, physicians, researchers, hospitals and laboratories.

At Roche we are committed to meeting high ethical standards and complying with all applicable local, national and international laws wherever we do business. Ethical behaviour in business is essential to creating and maintaining a healthy and just environment for all. For that reason, we maintain rigorous internal processes to ensure that our employees adhere to the laws, regulations and industry codes of conduct that support good business practices.

Roche fully endorses the Modern Slavery Act 2015 in order to eliminate all forms of human slavery, human trafficking and forced labour (“Modern Slavery”). Roche acknowledges the importance of companies working together to tackle such issues in our society and around the world. Roche condemns all forms of Modern Slavery including child, forced or compulsory labour. It is acknowledged by Roche and its staff that we all have a responsibility to be aware of Modern Slavery. Employees and business partners are requested to speak up and report incidents if they believe that someone has done, is doing, or may be about to do something that violates this principle.

Roche supports and respects human rights and has implemented the “Protect, Respect, Remedy” approach from theWe are equally committed to complying with the 10 UN Global Compact Principles; the Universal Declaration of Human Rights; and the Fundamental Labour Rights stipulated by the International Labour Organization’s Declaration on Fundamental Principles and Rights at Work. This commitment is embodied in our,,,, as well as in our. These policies clearly define our expectation for business behaviours.

Roche requires its business partners to comply with all applicable laws, regulations, industry codes and contractual terms as well as with generally accepted sustainability standards.

All transactions by Roche with third parties are made on the basis of quality, availability, service, suitability, sustainability and integrity. Roche remains committed to these principles and requires its suppliers to acknowledge and adhere to the principles embodied in its Supplier Code of Conduct and to ensure that their own suppliers will also comply with these principles. The Roche Supplier Code of Conduct comprises the principles of the Pharmaceutical Supply Chain Initiative (PSCI):

  •  Ethics: Suppliers shall conduct their business in an ethical manner and act with integrity.

  • Human Rights and Labour: Suppliers shall be committed to upholding the human rights of workers and treat them with dignity and respect.

  • Health and Safety: Suppliers shall provide a safe and healthy working environment, including for any company-provided living quarters.

  • Environment: Suppliers shall operate in an environmentally responsible and efficient manner, and they shall minimise adverse impacts on the environment.

  • Management Systems: Suppliers shall use management systems to facilitate continual improvement and compliance with the expectations of these principles.

Roche also has Compliance Officers in each country for issues relating to the implementation of and the compliance with the Roche Group Code of Conduct.

At Roche we understand that there is a potential exposure to Modern Slavery when we are purchasing goods and services from third parties. We continue to focus on the topic of Modern Slavery within our UK business operations, including reviewing the ethics of the suppliers that we work with and ensuring that their ethics and approach to Modern Slavery is included as part of our pre-engagement due diligence. Each Roche UK entity has continued with its own due diligence of its supply chain and, where appropriate, requested information from existing suppliers regarding their businesses, their position on the Modern Slavery Act 2015 and how they intend to eliminate Modern Slavery within their business and their own supply chains.

We have mapped our supply chains to assess particular industry/sector and geographical risk. These assessments cover the entire scope of our UK businesses.

Where suppliers operating in potentially higher risk areas have been identified, we have obtained copies of their policies and/or position relating to Modern Slavery. In some instances we require suppliers to enter into additional contractual arrangements to ensure that the services provided to Roche meet the requirements and standards expected from Roche in the UK.

To assist us in tackling the issue of Modern Slavery, we continue to remind our key suppliers of the Roche Supplier Code of Conduct and of our expectations in relation to adherence to all ethical standards expected of Roche suppliers, regardless of the area in which they operate.

All employees at Roche are trained on the Roche Group Code of Conduct which covers topics such as Human Rights. In addition, each Roche UK entity has documented internal operating procedures clarifying its employees’ responsibilities for compliance with the Modern Slavery Act 2015.

As a signatory of the UN Global Compact (UNGC) we commit to integrate the universal principles in the areas of human rights, labour, environment and anti-corruption into our business strategy, culture and daily operations and to report on the results achieved each year. 

Roche’s commitment to human rights is reflected in the stringent requirements we place on ourselves and on our more than 40,000 suppliers worldwide. We regard our suppliers and service providers as partners, and put our efforts into creating a relationship of mutual trust and collaboration in order to ensure that our standards are met.

One important element of these relationships is our Supplier Sustainability Assurance Visit programme (SSAV), which gives us the ability to positively impact labour conditions at our suppliers’ facilities. The Roche Supplier Code of Conduct binds our suppliers to adhere to clearly stated performance expectations, including performance on human rights, and allows Roche to conduct SSAVs to help ensure compliance through collaboration and capability building. All our suppliers are evaluated annually through a standardised, risk-based process to identify those at high risk for human rights violations against vulnerable populations (children, underage workers, migrants, local underprivileged communities and people with low levels of education). Suppliers determined to be at high risk are included in the SSAV programme.

Looking to the future, it is essential for us to constantly develop and expand our human rights requirements and guidelines in order to ensure we continue to meet the highest possible standards. In previous years, we updated our methodology to address industry sectors that were not previously considered, as well as non-Organisation for Economic Co-operation and Development (OECD) countries where performance standards may be lower, and human rights risks associated with certain commodities. To ensure we are properly addressing the issue of child labour, we also integrated the UNICEF Children’s Rights in the Workplace Index in our methodology for identifying high risk suppliers for inclusion into our SSAV programme.

Roche continues to collaborate on supplier audits with other pharmaceutical companies under the umbrella of the Pharmaceutical Supply Chain Initiative (PSCI) using a unified joint audit protocol.

Roche will continue to update its policies and procedures, raise awareness on this important topic and look at how it can address the issue of Modern Slavery within its business and supply chain. We will continue to work at maintaining appropriate safeguards against any mistreatment of persons involved in our supply chain or our own business.

This statement has been approved by the General Managers of Roche Products Limited, Roche Diagnostics Limited and Roche Diabetes Care Limited.

Richard Erwin
General Manager
Roche Products Limited

Geoff Twist
Managing Director
Roche Diagnostics Limited

Sean Gaffney
General Manager
Roche Diabetes Care Limited

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.